Phase IIA, Multicenter, Randomized, Third-Party Unblinded, Adjuvant And Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of ACC-001 And QS-21 Adjuvant In Subjects With Mild To Moderate Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs QS 21 (Primary) ; Vanutide cridificar (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT00498602).
- 09 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov (Parent trial: NCT00498602).